Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07137793 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Study acronym: PTX / BC
StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: May 25, 2025 to Sep 1, 2025 Trial completed · Primary completion date changed from estimate of May 2026 to Mar 15, 2026 · Study completion date changed from estimate of Dec 2026 to Sep 23, 2026 · 3 more Show 6 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of May 2026 to Mar 15, 2026
    • Study completion date changed from estimate of Dec 2026 to Sep 23, 2026
    • Eligibility criteria expanded, about 16 words
    • Site details revised
    • Publications: details revised at 3 of 3 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tanta University
394 trials monitored
See 11 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
The goal of this clinical trial is to evaluate the cardioprotective effect of pentoxifylline against doxorubicin-induced cardiotoxicity in breast cancer patients. The main questions it aims to answer are: 1. What is the change in ejection fraction (primary outcome) in breast cancer patients receiving pentoxifylline compared to those who do not? 2. What are the changes in serum levels of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), and TNF-α (secondary outcomes) in breast cancer patients receiving pentoxifylline compared to those who do not? Researcher will compare breast cancer patients receiving standard chemotherapy alone (Group one: Positive control group; n=23) to breast cancer patients receiving standard chemotherapy plus pentoxifylline (Group two: pentoxifylline group; n=23) to see if pentoxifylline mitigates the cardiac side effects associated with doxorubicin treatment. Participants will: Be randomized to receive either a chemotherapeutic regimen alone or with pentoxifylline.
Trial Details
NCT Number NCT07137793
Lead Sponsor Tanta University
Conditions Doxorubicin Induced Cardiotoxicity, Breast Cancer
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov